KPV

KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH), specifically representing the last three amino acids of the 13-amino-acid parent peptide. As a research peptide, KPV has attracted significant scientific interest for its anti-inflammatory, antimicrobial, and wound-healing properties that appear to operate through melanocortin receptor-independent pathways.

Mechanism of Action

KPV exerts its biological effects primarily through interaction with the melanocortin-1 receptor (MC1R) and intracellular inflammatory signaling cascades. Research suggests that KPV can penetrate cell membranes and act directly within the cytoplasm, where it modulates nuclear factor-kappa B (NF-κB) signaling—a central mediator of inflammatory gene expression. By inhibiting NF-κB activation, KPV reduces the transcription of pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β).

Unlike the full α-MSH molecule, KPV maintains anti-inflammatory activity while being considerably smaller (molecular weight approximately 326 Da), which may facilitate cellular uptake and tissue penetration. In vitro studies have demonstrated KPV's ability to reduce lipopolysaccharide (LPS)-induced inflammatory responses in macrophages and epithelial cells. The peptide also appears to interact with non-receptor intracellular targets, suggesting a complex, multi-pathway mechanism that researchers continue to investigate.

The tripeptide sequence Lys-Pro-Val is conserved across species, pointing to its evolutionary significance in modulating inflammatory responses. Research has shown that KPV can cross epithelial barriers, making it relevant to studies of mucosal immunity and gastrointestinal inflammation.

Research Applications and Published Findings

Gastrointestinal Inflammation Studies

One of the most extensively studied applications of KPV in research is its effect on intestinal inflammation. Animal models of inflammatory bowel disease (IBD), including experimental colitis induced by dextran sodium sulfate (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS), have consistently shown that KPV administration reduces histological damage, inflammatory cell infiltration, and pro-inflammatory cytokine production.

A pivotal study published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that intracolonic administration of KPV significantly reduced mucosal inflammation in murine colitis models. The research team found that KPV achieved therapeutic effects comparable to conventional anti-inflammatory treatments at the mucosal site, suggesting potential relevance for localized gastrointestinal applications.

Subsequent work examined oral bioavailability concerns by encapsulating KPV in nanoparticle delivery systems. These hydrogel nanoparticles were shown to protect KPV from proteolytic degradation in the gastrointestinal tract while enabling sustained release at the colonic mucosa. Research using these delivery systems demonstrated that orally administered nanoparticle-encapsulated KPV reduced colitis severity in mouse models, opening discussion of delivery challenges inherent to peptide therapeutics.

Wound Healing and Skin Research

KPV's wound-healing properties have been examined in multiple preclinical contexts. Studies indicate that KPV promotes keratinocyte migration—a critical step in re-epithelialization—and reduces inflammatory mediators at wound sites. Research published in dermatology-adjacent journals has explored KPV's potential in psoriasis models, where the peptide reduced epidermal hyperplasia and inflammatory infiltrates.

The antimicrobial properties of KPV have also been characterized. In vitro studies show that KPV exhibits activity against certain bacterial strains, including Staphylococcus aureus and Pseudomonas aeruginosa, which are commonly implicated in wound infections. This dual anti-inflammatory and antimicrobial activity positions KPV as an interesting research tool for studying tissue repair and infection-associated inflammation.

Systemic Inflammation Models

Beyond localized applications, KPV has been studied in models of systemic inflammation. Research has examined its effects on fever reduction (antipyretic activity), leveraging its relationship to α-MSH, which is known to be involved in thermoregulatory responses. Studies have also explored KPV in the context of sepsis models, where reduction of systemic inflammatory mediators is a primary research objective.

In neuroinflammation research, KPV has been investigated for its potential to modulate microglial activation and reduce neuroinflammatory markers in animal models of brain injury and neurodegeneration. While these findings are preliminary and limited to preclinical settings, they contribute to the broader understanding of melanocortin-derived peptide fragments in central nervous system inflammation.

Physicochemical Properties

KPV presents as a white to off-white lyophilized powder under standard research conditions. Its molecular formula is C₁₄H₂₇N₃O₄, with a molecular weight of approximately 301.38 Da (as the free base) or 326–340 Da depending on the salt form.

Key physicochemical characteristics: - **Solubility:** Freely soluble in water and phosphate-buffered saline (PBS); also soluble in dimethyl sulfoxide (DMSO) for in vitro applications - **pH stability:** Most stable at slightly acidic to neutral pH (4.5–7.4); degrades more rapidly under strongly alkaline conditions - **Temperature stability:** Lyophilized powder stable at -20°C for extended storage; reconstituted solutions should be used promptly or stored at 4°C for short-term use (up to 1 week) or -20°C (up to 3 months) with appropriate protease inhibitors if needed - **Purity standards:** Research-grade KPV is typically available at ≥95% purity (HPLC-confirmed), with mass spectrometry verification included in certificates of analysis

Reconstitution and Handling for Research

For standard in vitro applications, KPV is commonly reconstituted in sterile water or phosphate-buffered saline (PBS) to yield stock concentrations between 1–10 mg/mL. For cell culture experiments, reconstitution in cell culture-grade water or appropriate buffer ensures compatibility with biological assays.

**Recommended storage protocol:** 1. Keep lyophilized peptide at -20°C (or -80°C for long-term storage) until use 2. Allow vial to equilibrate to room temperature before opening to minimize condensation 3. Add diluent slowly to the lyophilized powder (not vice versa) to maintain homogeneity 4. Aliquot into single-use volumes to minimize freeze-thaw cycles 5. Reconstituted solutions should be aliquoted and stored at -20°C; avoid repeated freeze-thaw beyond 3 cycles

Research Context and Regulatory Status

KPV is sold exclusively for in vitro and animal research purposes. It is not approved by the FDA or any equivalent regulatory authority for human use, and no clinical trials for KPV have been completed or approved in the United States. All published research on KPV has been conducted in cell culture systems and animal models.

Researchers working with KPV should ensure compliance with their institutional biosafety protocols and relevant regulations governing peptide research. As with all research peptides, KPV is intended for laboratory use only and must not be administered to humans.

The growing body of preclinical evidence for KPV in inflammatory conditions has generated interest in its potential as a research scaffold for understanding melanocortin-related biology. However, the translation of these findings to human biology remains speculative pending controlled clinical investigation.

Comparison with Parent Peptide α-MSH

KPV represents the C-terminal tripeptide of α-MSH (sequence: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂). Research has compared KPV directly to its parent molecule to understand which structural features are responsible for observed biological activities.

Key differences in research models: - **Receptor binding:** α-MSH binds with high affinity to MC1R, MC3R, MC4R, and MC5R; KPV shows weaker but measurable MC1R affinity and may act through additional intracellular mechanisms - **Stability:** KPV is more resistant to proteolytic degradation than the full α-MSH sequence, which may be relevant to in vivo pharmacokinetic studies - **CNS penetration:** Research suggests KPV may have limited blood-brain barrier penetration compared to α-MSH under standard conditions, though this varies by delivery method - **Anti-inflammatory potency:** Some studies report that KPV maintains approximately 20–40% of α-MSH's anti-inflammatory potency on a molar basis, while other experimental contexts show comparable effects, particularly in epithelial and mucosal systems

Understanding these distinctions guides researchers in designing experiments that appropriately leverage KPV as a tool compound for studying melanocortin biology.

Related Research Peptides

Researchers studying KPV often investigate related melanocortin-derived peptides as complementary tools: - **α-MSH:** The parent peptide; broader receptor binding and CNS activity - **[D-Phe7]-α-MSH:** An analog with enhanced metabolic stability - **GHK-Cu:** Another anti-inflammatory peptide used in wound healing and skin research - **BPC-157:** A pentadecapeptide with overlapping gastrointestinal protective properties in research models - **Thymosin Beta-4 (TB-500):** Studied alongside KPV in wound repair and inflammatory reduction research

All research peptides should be sourced from suppliers who provide current certificates of analysis, including HPLC purity data, mass spectrometry confirmation, and endotoxin testing results. For research applications, quality control documentation is essential for reproducibility and scientific rigor.